Hier die letzten Meldungen:
Sanofi-Aventis SA' s Subsidiary Partners with KaloBios on Novel Biologic
Monday, 11 Jan 2010 04:20am EST
Sanofi-Aventis SA announced that its subsidiary, Sanofi Pasteur, partners with KaloBios on Novel Biologic for the development of a Humaneered antibody fragment to both treat and prevent Pseudomonas aeruginosa (Pa) infections.
sanofi-aventis' Subsidiary Commences Tender Offer For All Outstanding Shares Of Chattem, Inc.
Monday, 11 Jan 2010 01:00am EST
sanofi-aventis announced the commencement of a tender offer through its wholly owned subsidiary, River Acquisition Corp., for all outstanding shares of common stock of Chattem, Inc. for $93.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated January 11, 2010, and in connection with the previously announced Agreement and Plan of Merger, dated December 20, 2009, among sanofi-aventis, River Acquisition Corp. and Chattem, Inc. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on February 8, 2010, unless the tender offer is extended. Following the successful completion of the tender offer, sanofi-aventis' wholly owned subsidiary, River Acquisition Corp., will merge with and into Chattem and the outstanding Chattem shares not tendered in the tender offer will be converted into the right to receive the same $93.50 per share in cash paid in the tender offer.
France Cancels 50 Million Flu Shot Orders From sanofi-aventis And Others-Reuters
Monday, 4 Jan 2010 04:37pm EST
Reuters reported that France has cancelled over half the flu vaccines it ordered to combat the H1N1 flu virus, Health Minister Roselyne Bachelot said, in an effort to head off criticism after reserving too many shots. France ordered the vaccinations from Sanofi-Pasteur, a unit of sanofi-aventis, GlaxoSmithKline plc , Novartis AG and Baxter International Inc. The government estimated 94 million individual shots were needed, thinking that everyone would need two jabs for immunity against the illness. Doctors now say a single vaccination is sufficient, meaning that France, with a population of some 65 million has a massive oversupply and is already trying to sell on some of the surplus shots it has received.
FDA Licenses sanofi-aventis Subsidiary's New Influenza Vaccine
Wednesday, 23 Dec 2009 05:26pm EST
Sanofi Pasteur, the vaccines division of the sanofi-aventis, announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental biologics license application (sBLA) for licensure of Fluzone High-Dose (Influenza Virus Vaccine). The new vaccine, for adults 65 years of age and older, will be available to health-care providers for immunizations administered this fall in preparation for the upcoming 2010-2011 influenza season.
Sanofi-Aventis SA May Take Zealand Pharma Stake-Reuters
Wednesday, 23 Dec 2009 02:59am EST
Reuters reported that, according to Les Echos, Sanofi-Aventis SA is considering taking a stake of up to 19.9% in Danish biotech Zealand Pharma for up to EUR100 million ($143.1 million).
sanofi-aventis To Acquire Chattem, Inc.
Monday, 21 Dec 2009 07:21am EST
sanofi-aventis and Chattem, Inc. announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire 100% of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion. Under the terms of the agreement, sanofi-aventis will commence a tender offer for all outstanding shares of Chattem at $93.50 per share in cash. The offer price represents a 34% premium above the closing price of Chattem's shares on December 18, 2009 and a 44% premium above the average closing price of Chattem's shares during the six months preceding the announcement of the transaction. The tender offer is conditioned on the tender of a majority of Chattem's shares calculated on a diluted basis, as well as the receipt of certain regulatory approvals and other customary closing conditions. Following the completion of the tender offer, a wholly owned subsidiary of sanofi-aventis will merge with Chattem and the outstanding Chattem shares not tendered in the tender offer will be converted into the right to receive the same $ 93.50 per share in cash paid in the tender offer. The tender offer will commence in January 2010, and the companies anticipate the transaction will close in the first quarter of 2010. Chattem's Board of Directors has unanimously approved the transaction.
Sanofi-Aventis SA Discontinues Eplivanserin For Insomnia-DJ
Monday, 21 Dec 2009 01:25am EST
Dow Jones reported that Sanofi-Aventis SA said it's discontinuing the development of two drugs, eplivanserin for insomnia and idrabiotaparinux for atrial fibrillation. In a statement updating the situation in its research and development pipeline, which the Company has streamlined since the arrival of Chief Executive Chris Viehbacher, Sanofi-Aventis said it was withdrawing its application with U.S. and European authorities for the eplivanserin insomnia treatment after a letter from the U.S. Food and Drug Administration in September. As for the idrabiotaparinux heart treatment, Sanofi cited a lack of significant improvement for patients from the compound as the reason for discontinuing its development. Sanofi-Aventis SA has pared down its pipeline of drug development under the leadership of Viehbacher, who has stressed partnerships and acquisitions for obtaining new drugs. Sanofi-Aventis SA also said that the FDA has granted fast track processing to its prostate cancer treatment cabazitaxel and that the European medicines Agency issued a positive opinion and a recommendation to grant marketing authorization for its DuoPlavin coronary treatment.
AEterna Zentaris Inc. Announces Termination Of Agreement With Sanofi-Aventis SA's sanofi-aventis U.S. For Development, Commercialization And Licensing Of Cetrorelix In Benign Prostatic Hyperplasia
Friday, 18 Dec 2009 07:15am EST
AEterna Zentaris Inc. announced the termination of its agreement with Sanofi-Aventis SA's sanofi-aventis U.S., dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following AEterna Zentaris's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH. Termination of the agreement will be effective January 9, 2010. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a Phase 3 program in BPH, a non-cancerous enlargement of the prostate which, as announced by AEterna Zentaris last week, did not meet its primary endpoint.
Sanofi-Aventis's Sanofi Pasteur Obtains License From Syntiron To Develop And Commercialize Vaccine To Prevent Staphylococcus Infections-Complete Story
Wednesday, 16 Dec 2009 09:00am EST
Sanofi Pasteur, the vaccines division of Sanofi-Aventis announced that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA. MRSA are responsible for several difficult-to-treat infections in humans, sometimes referred to as multidrug-resistant Staphylococcus aureus because these bacteria are resistant to a large group of antibiotics, including penicillins. Syntiron is a private biotech company located in St. Paul, Minnesota; its mission is the prevention and treatment of human disease resulting from bacterial infection. Under the terms of the agreement, Sanofi Pasteur will support the joint, pre-clinical development of the product, working cooperatively with Syntiron, and be responsible for all future developments, regulatory approval, and commercialization of the vaccine. The agreement includes an undisclosed initial licensing fee, milestone payments, and royalty payments on future sales of the product.
sanofi-aventis Recalling 800,000 Doses Of Children's H1N1 Vaccine-DJ
Tuesday, 15 Dec 2009 11:48am EST
Dow Jones reported that according to the Centers for Disease Control and Prevention, sanofi-aventis is recalling about 800,000 doses of children's H1N1 vaccine after tests showed the some batches of the vaccine didn't meet potency standards. The CDC said there are no safety concerns with the recalled vaccine, which involves four lots, or batches. The CDC said the vaccine's potency, which is a measure of the strength of the active ingredient in the vaccine, 'is only slightly below the specified range.' CDC also said the vaccine in the recalled lots is still expected to be effective in stimulating a protective response against the H1N1 virus.
|aus der Diskussion:||Sanofi-Aventis meldet ersten Erfolg aus Studie zu HIV-Impfstoff|
|Autor (Datum des Eintrages):||Poppholz (12.01.10 13:01:27)|
|Beitrag:||27 von 27 (ID:38716666)|
|Alle Angaben ohne Gewähr © wallstreet:online|